Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Celgene
The purpose of this study is to characterize the full pharmacokinetic and pharmacodynamics profiles of RPC1063 in patients with relapsing multiple sclerosis (RMS) following multiple-dose administration of the two different dosing regimens that are being evaluated in the Phase 3 RMS studies.
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
MS, as diagnosed by the revised 2010 McDonald criteria
Exhibits a relapsing clinical course consistent with RMS and history of brain MRI lesions consistent with MS
Expanded disability status scale (EDSS) score between 0 and 6.0
You may not be if
Primary progressive MS
Clinically relevant cardiovascular conditions or other relevant diseases that could impact the implementation or interpretation of the trial, or put the patient at risk
